Chapter One Advisors
Highlights
- Record revenue and cash receipts
- Revenue of $10.2 million (unaudited), up 40% on prior quarter
- Cash receipts of $10.8 million, up over 30% on prior quarter
- Net operating cash inflow of over $1.0 million resulting in cashflow positive quarter of $0.6 million
- Cost savings of $0.5 million per year expected from subcontracting Australian cultivation operations
- German, UK and French cannabis markets driving strong growth in European industry demand
- Cash in bank of $4.8 million up from $4.3 million
Little Green Pharma (ASX:LGP) has delivered a robust performance in the September quarter, achieving record revenue and cash receipts.
The company reported unaudited revenue of $10.2 million, reflecting a 40% increase over the prior quarter, while cash receipts rose over 30% to reach $10.8 million.
This strong financial performance led to a net operating cash inflow of more than $1.0 million, resulting in a cashflow positive quarter of $0.6 million.
Growth in the European cannabis market, particularly in Germany, the UK, and France, continues to drive demand.
With cash in the bank increasing to $4.8 million from $4.3 million, Little Green Pharma is well-positioned for continued expansion.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).
